Condition: Basal Cell Carcinoma · Sponsor: University of California, San Diego
This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
This description comes directly from the study's public registry record.
Catherine O'Neil, BS · 858-822-5354 · CancerCTO@health.ucsd.edu
Always discuss trial participation with your own doctor first.
| University of California, Irvine | Irvine, California, United States | Recruiting |
| University of California, San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06624475